Oklahoma Clinical Trials Report — June 2026

For Oklahomans considering participation in clinical research, June 2026 presents a crucial window for trials nearing their conclusion, alongside a significant increase in new opportunities. Across the state, 38 clinical trials are slated to close within the next 90 days, meaning time is running out to enroll. This includes 3 studies actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

This month also brings a notable surge in new research, with 18 trials opening their doors – a substantial increase from the 10 that began in May 2026. These new studies span a variety of health areas, from chronic conditions to acute medical interventions, and include major initiatives from leading pharmaceutical companies.

Act Now: Trials Closing Soon Across Oklahoma

Individuals living with certain health conditions should act quickly to explore trials with impending deadlines. Research focusing on neurological conditions, mental health, and various cancers are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Stroke
• Major depressive disorder
• Advanced malignant neoplasm
• Advanced solid tumor
• Aggression
• Agitation, psychomotor
• Alzheimer disease
• Alcohol use disorder
• AML
• AML with mutated NPM1

If you or someone you know is affected by these conditions, reviewing these opportunities promptly is essential. Even for healthy volunteers, the 3 trials closing soon represent a time-sensitive chance to participate in medical advancement.

Groundbreaking Research Launches This Month

Oklahoma's clinical research landscape is expanding rapidly, with 18 new trials opening this June. This robust activity contributes to the state's total of 766 clinical trials currently recruiting across 23 cities and 388 research sites. The new studies offer diverse opportunities, with a strong emphasis on drug development, accounting for 12 of the new trials. Device and behavioral studies also contribute to this month's openings.

Several major pharmaceutical companies and academic institutions are sponsoring significant new research initiatives, bringing cutting-edge treatments and diagnostics to Oklahoma. Notable new trials include:

• AstraZeneca is sponsoring NCT07667803, a Phase 3 "Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM." This substantial global study aims to enroll 4,500 participants, evaluating a new treatment for weight management.
• Another major Phase 3 trial, NCT07654361, is "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)," sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. This global study seeks 3,600 participants to assess the long-term efficacy, safety, and tolerability of aleniglipron.
• For those with type 2 diabetes, AstraZeneca is also sponsoring NCT07662213, a Phase 3 study investigating "A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus." This trial plans for 1,200 participants.
• A related Phase 3 study, NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)," is also sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, and will enroll 1,100 participants to evaluate aleniglipron in individuals with both conditions.
• Individuals experiencing migraines may be interested in two Phase 3 trials from Kallyope Inc.: NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," targeting 1,800 participants, and NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine," seeking 1,000 participants.
• Beyond drug development, the Office of the Medical Director for EMS in Oklahoma City and Tulsa is leading NCT07632430, "End-Tidal CO2 (ETCO2) Trends in Out-of-Hospital Cardiac Arrest." This important study aims to enroll 3,500 participants to assess predictors of survival for cardiac arrest patients.
• The University of Alabama at Birmingham is sponsoring NCT07671937, "INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study," which plans to enroll 2,748 participants to improve cancer treatment recommendations.

Diverse Conditions and Growing Opportunities

The 18 new trials opening this month in Oklahoma cover a diverse range of health conditions, with a strong focus on metabolic health and pain management. The most common conditions addressed by these new studies include:

• Obesity
• Overweight
• Chronic pain
• Chronic weight management
• Cardiac arrest, out-of-hospital
• Chronic wounds
• Corpus uteri cancer
• Diabetes mellitus, type 2
• Diabetic foot
• Diabetic foot ulcers (DFUs)

Industry sponsors are driving a significant portion of this month's research, with 12 new trials. Academic institutions, including the University of Oklahoma, are also contributing substantially, sponsoring 4 new studies, ensuring a blend of commercial and publicly funded research initiatives.

Geographic Reach: Metro Areas Lead the Way

Oklahoma's clinical research opportunities are largely concentrated in its major metropolitan areas, making access convenient for many residents. This month, the majority of new research initiatives are centered in:

• Oklahoma City (10 new trials)
• Tulsa (8 new trials)
• Yukon (4 new trials)
• Edmond (2 new trials)
• Moore (2 new trials)

This distribution ensures that residents in these urban and suburban hubs have direct access to cutting-edge research, while the statewide total of 23 cities with recruiting trials indicates broader, though less concentrated, opportunities.

Healthy Volunteers and Inclusive Participation

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 18 new trials launched this month, 2 are actively seeking healthy volunteers. Statewide, a total of 53 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Oklahoma are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 2 include children as participants, and 17 include older adults, ensuring that research benefits diverse age groups. There are no new trials this month exclusively for females or males, indicating a focus on broader population studies.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Oklahoma. We encourage all interested individuals to explore these opportunities and consider contributing to the future of health.